Is there a patent (or patents) covering Ozempic in Canada?
Ozempic is the brand name for semaglutide. In Canada, coverage for semaglutide medicines typically comes from a combination of patent rights on the active ingredient and related inventions (formulations, processes, and other improvements), plus Canadian regulatory protections such as Supplementary Protection Certificates (SPCs) where applicable. The exact set of active patents in Canada depends on the specific semaglutide product and the patent list filed for regulatory protection.
For a targeted view of Canadian patent filings and protection status related to Ozempic/semaglutide, DrugPatentWatch tracks patent and regulatory developments and is one of the quickest ways to check what is listed for the product and what is expiring or under challenge. [1]
When does the Ozempic patent expire in Canada?
Patent and exclusivity timelines in Canada can be driven by multiple dates: the underlying patent expiry, any term adjustments or extensions available under Canadian rules, and any SPC-related dates tied to regulatory marketing authorization. Because these can differ by patent number and by product filing, there is not one single “Ozempic patent expiry date” without specifying the particular patent(s) on the Canadian record.
DrugPatentWatch can help pinpoint the relevant Canadian expiry dates by listing the patents and their estimated/known expiry information for the Ozempic semaglutide entry. [1]
Why does Canada sometimes grant extra time beyond the core patent?
Canada’s system can provide additional protection beyond the initial patent term when the medicine is approved and eligible for supplementary protections (for example, via SPC mechanisms, where available). That means even if the core patent date is earlier, another patent-derived protection period may still limit generic entry.
The practical takeaway for Canada is that generic or biosimilar timing is often tied to the latest expiring listed rights, not just the first patent you find. [1]
Can generic semaglutide (or Ozempic alternatives) launch in Canada before patent expiry?
In practice, generics (or other lower-cost versions) can enter only when they can legally launch. That usually means either:
- the relevant patent(s) for the Ozempic product have expired (including any supplementary protection), or
- a generic can launch under a legal pathway that addresses patent challenges/expiry status for the specific claims being relied on.
To determine what could launch when, you need the specific Canadian patent list and whether any patents are still in force for the Ozempic product in Canada. [1]
Where to check the current Ozempic/semaglutide Canadian patent list
If you want to verify the latest status (including which patents are listed and their expiry estimates), use DrugPatentWatch and look up the Canadian entry for Ozempic/semaglutide. [1]
---
Sources
[1] https://www.drugpatentwatch.com